The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Lauren Collison, PhD, Senior VP, Operations & Site Head, KBI Biopharma, reflects. The individual successes within the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!